Business Context and Reporting Period
Company: The Cooper Companies, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: July 31, 2002
Business Overview: Cooper operates two primary segments: CooperVision (CVI), which markets specialty contact lenses, and CooperSurgical (CSI), which markets medical devices and surgical instruments for gynecology and obstetrics. The company is headquartered in Pleasanton, California.
Key Financial Metrics
| Metric | Three Months Ended July 31, 2002 |
Nine Months Ended July 31, 2002 |
Nine Months Ended July 31, 2001 |
|---|---|---|---|
| Net Sales | $90.6 million | $220.6 million | $168.5 million |
| Gross Profit | $55.7 million | $137.4 million | $109.7 million |
| Gross Margin | 62% | 62% | 65% |
| Operating Income | $17.0 million | $44.8 million | $37.3 million |
| Net Income | $13.4 million | $32.7 million | $25.4 million |
| Diluted EPS | $0.86 | $2.10 | $1.68 |
| Cash from Operations | N/A | $39.9 million | $19.9 million |
| Total Debt | $168.3 million | $168.3 million | $68.8 million (Oct 31, 2001) |
| Cash & Equivalents | $8.8 million | $8.8 million | $12.9 million (Oct 31, 2001) |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 48% in the third quarter and 31% year-to-date compared to the prior year. This growth was significantly driven by the acquisition of Biocompatibles International plc (completed Feb 2002), Ackrad Laboratories (May 2002), and Norland Medical Systems (April 2002).
- Profitability: Operating income rose 21% in the quarter and 20% year-to-date. Diluted EPS increased 28% in the quarter and 25% year-to-date.
- Margins: Consolidated gross margin decreased slightly to 62% from 64% in the prior year quarter, attributed to a higher mix of distributor sales (which carry lower margins) and a $2 million charge at CSI to phase out the Cerveillance colposcopy system.
- Debt Levels: Total debt more than tripled from $68.8 million (Oct 31, 2001) to $168.3 million (July 31, 2002) to fund acquisitions. Interest expense increased 157% in the quarter.
- Accounting Changes: The company adopted SFAS 142, eliminating goodwill amortization. This resulted in a reduction of amortization expense from $1.5 million to $0.6 million in the quarter.
Guidance, Outlook, and Risks
- Outlook: Management expects the effective tax rate for fiscal 2002 to be 27%, declining to approximately 26% in fiscal 2003 due to the geographic mix of income. CVI targets a 30% operating income margin mid-term as integration of Biocompatibles completes.
- Liquidity: The company expanded its credit facility to $225 million in May 2002. As of July 31, 2002, $62.7 million remained available. Management believes operating cash flow and existing credit facilities will fund operations, dividends, and smaller acquisitions.
- Legal Contingencies: CooperVision is involved in patent litigation with CIBA Vision regarding cosmetic contact lenses. A U.S. court granted summary judgment of infringement on one patent, though CooperVision is challenging the patent's validity. Revenue from disputed products represents approximately 2% of year-to-date revenue.
- Market Risks: The company faces exposure to foreign exchange fluctuations (primarily British pound) and variable interest rates on approximately $135 million of debt.
Investor Verification Checklist
- Acquisition Integration: Verify the realization of synergies and margin improvements from the Biocompatibles, Ackrad, and Norland acquisitions.
- Debt Servicing: Monitor the company's ability to service the increased debt load ($168.3 million) and compliance with debt covenants (e.g., debt-to-EBITDA ratio).
- Patent Litigation: Track the outcome of the CIBA Vision patent disputes, specifically the validity challenges to the '477 and '240 patents.
- Working Capital: Observe Days Sales Outstanding (DSO), which improved to 69 days but remains elevated due to prior ERP system issues.
- Product Mix Shift: Assess the long-term impact of the shift toward distributor sales on gross margins versus the offsetting reduction in operating expenses.